Circulating Lncrnas Acting As Diagnosis Fingerprints For Predicting Triple Negative Breast Cancer

The long non-coding RNAs (lncRNAs) has been identified as non-invasive markers in both diagnosis and predicting the prognosis of human malignant tumors. Here we mainly focused on the circulating expressed lncRNAs in triple negative breast cancer patients (TNBC) to screen potential lncRNAs as diagnosis fingerprint. All the studies focusing on the lncRNA in TNBC, we found 14 lncRNAs whom has been identified with significant increased level in TNBC tumor tissues. According to previously report, we enrolled 14 lncRNAs whom has been identified with significant increased level in TNBC tumor tissues, as candidate based on their aberrant expression in TNBC patients. The screening phase revealed that ANRIL, SOX2OT and ANRASSF1 presenting with increased level (p<0.05) in 20 paired TNBC patients, non-TNBC patients and controls. Further validation set also confirmed the increasing level of these three lncRNAs by Quantitative real-time PCR (qRT-PCR). The risk score analysis presenting by receiver operating characteristic curve (ROC) indicating ANRIL, SOX2OT and ANRASSF1 could distinguish TNBC patients from the non-TNBC patients. Amongthis, ANRIL provided the highest diagnostic performance with an area under ROC curve value (AUC) of 0.918. Further combination with the three factors indicated a higher power (AUC, 0.959; sensitivity, 92.8%; specificity, 90.5%). In conclusion, circulating lncRNAs ANRIL, SOX2OT and ANRASSF1 might act as fingerprints for predicting triple negative breast cancer.